Douglas B. Johnson

47.0k citations

293 papers · 14.1k indexed · 10 hit papers · h-index 59

Impact in

Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Cutaneous Melanoma Detection and Management
Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in

Oncology 252
- Cancer Immunotherapy and Biomarkers 190
- CAR-T cell therapy research 93
- Cutaneous Melanoma Detection and Management 43
- Colorectal Cancer Treatments and Studies 33
Immunology 81
- Immunotherapy and Immune Responses 62

Co-authors: Jeffrey A. Sosman Justin M. Balko Satya Das Javid J. Moslehi Ryan J. Sullivan Caroline A. Nebhan Alexander M. Menzies Igor Puzanov
Journals: Journal of Clinical Oncology (56 papers)Journal for ImmunoTherapy of Cancer (20 papers)The Oncologist (19 papers)Annals of Oncology (12 papers)Cancer Immunology Research (11 papers)
Partner nations: United States Australia Germany

In The Last Decade

Douglas B. Johnson

281 papers receiving 13.9k citations

Hit Papers

10 papers align trajectories log scale

Immune-checkpoint inhibitors: long-term implications of toxicity 2022 · 610 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Nature Reviews Clinical Oncology
2021 Nature Reviews Endocrinology
2019 JAMA Oncology
2019 Journal for ImmunoTherapy of Cancer
2019 Cardiovascular Research
2019 Nature Nanotechnology
2019 Journal for ImmunoTherapy of Cancer
2016 Annals of Oncology
2015 Cell
2013 Cancer Discovery

Peers

Countries citing papers authored by Douglas B. Johnson

Since Specialization

Citations

This map shows the geographic impact of Douglas B. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas B. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas B. Johnson more than expected).

Fields of papers citing papers by Douglas B. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas B. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas B. Johnson. The network helps show where Douglas B. Johnson may publish in the future.

Co-authors

The 25 scholars most cited alongside Douglas B. Johnson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Douglas B. Johnson Line = papers co-authored together Douglas B. Johnson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series The Oncologist ·Rachel Goodman, Alejandro Pascual Valdunciel, Caixia Feng, Douglas B. Johnson	2023	1
2	Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma JAMA Network Open ·Rachel Goodman, Aleigha Lawless, Rachel Woodford, Faisal Fa’ak, E Champ Colin, James R. Patrinely, Hui‐Ling Yeoh, Suthee Rapisuwon, Andrew Haydon, Iman Osman, Janice M. Mehnert, Georgina V. Long, Ryan J. Sullivan, Matteo S. Carlino, Alexander M. Menzies, Douglas B. Johnson	2023	30
3	Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study European Journal of Cancer ·Patricio Serra-Bellver, Judith M. Versluis, Pujit Kumar Nahata, Cong Zhou, Mojian Zhang, Yasir Khan, James R. Patrinely, Inês Pires da Silva, Clara Martínez-Vila, Natalie Cook, Donna M. Graham, Matteo S. Carlino, Alexander M. Menzies, Ana Arance, Douglas B. Johnson, Georgina V. Long, Lisa Pickering, James Larkin, Christian U. Blank, Paul Lorigan	2022	14
4	Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma Clinical Cancer Research ·Paul Johannet, Nicolas Coudray, Douglas M. Donnelly, George Jour, Irineu Illa-Bochaca, Yuhe Xia, Douglas B. Johnson, Lee Wheless, James R. Patrinely, Sofia Nomikou, David L. Rimm, Anna C. Pavlick, Jeffrey S. Weber, Judy Zhong, Aristotelis Tsirigos, Iman Osman	2020	114
5	Demographic Factors Associated with Toxicity in Patients Treated with Anti–Programmed Cell Death-1 Therapy Cancer Immunology Research ·Sabina Bodył-Gajowska, Haocan Song, Fei Ye, Javid J. Moslehi, Justin M. Balko, Joe‐Elie Salem, Douglas B. Johnson	2020	42
6	Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations Molecular Cancer Research ·Brian D. Lehmann, Timothy M. Shaver, Douglas B. Johnson, Zhu Li, Paula I. González-Ericsson, Violeta Sánchez, Yu Shyr, Melinda E. Sanders, Jennifer A. Pietenpol	2019	11
7	Anti–PD-1–Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients Cancer Immunology Research ·Douglas B. Johnson, A. Mailliani, Justine V. Cohen, Fita Ardianasari, Alexandra M. Haugh, Daniel Wang, 誠二股, Mercè Alemany Chavarria, Kenneth L. Gage, Florian J. Fintelmann, Ryan J. Sullivan, Zeynep Eroglu, Richard G. Abramson	2019	20
8	Hematologic Complications of Immune Checkpoint Inhibitors The Oncologist ·Elizabeth J. Davis, Joe‐Elie Salem, Arissa Young, YUANWen-Jun等, P. Brent Ferrell, Kristin Kathleen Ancell, Bénédicte Lebrun‐Vignes, Javid J. Moslehi, Douglas B. Johnson	2019	115
9	Health care utilization and steroid‐refractory toxicities from immune checkpoint inhibitors Cancer ·Terezie Husarová, Henry T. Quach, A.S. Kuncoro, Elizabeth J. Davis, Jeffrey A. Sosman, Stacie B. Dusetzina, Douglas B. Johnson	2019	14
10	Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types Cancer Immunology Research ·Allison R. Greenplate, 祐吉天野, 澤観海老, Deon B. Doxie, Nathália Barbosa do Espírito Santo Borges, Kirsten E. Diggins, Nalin Leelatian, Megan L. Rasmussen, Mark C. Kelley, Vivian Gama, Peter J. Siska, Jeffrey C. Rathmell, P. Brent Ferrell, Douglas B. Johnson, Jonathan M. Irish	2018	21
11	Melanoma: What do all the mutations mean? Cancer ·Elizabeth J. Davis, Douglas B. Johnson, Jeffrey A. Sosman, Sunandana Chandra	2018	121
12	Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma Cancer Immunology Research ·Daniel Wang, Zeynep Eroglu, Alpaslan Özgün, Paul Leger, Shilin Zhao, Fei Ye, Jason J. Luke, Richard W. Joseph, Rizwan Haq, Patrick A. Ott, F. Stephen Hodi, Jeffrey A. Sosman, Douglas B. Johnson, Elizabeth I. Buchbinder	2017	35
13	Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Cancer Discovery ·Chunying Song, Marco Piva, Lu Sun, Aayoung Hong, Gatien Moriceau, Xiangju Kong, Hong Zhang, Shirley H. Lomeli, Jin Qian, Clarissa C. Yu, Robert Damoiseaux, Mark C. Kelley, Lars Badde, Philip O. Scumpia, Jeffrey A. Sosman, Douglas B. Johnson, Antoni Ribas, Willy Hugo, Roger S. Lo	2017	109
14	Regional Lymph Node Basin (RLNB) Relapse after Adjuvant Ipilimumab (Ipi) Anti-CTLA4 Immunotherapy in Stage III Melanoma: A Subgroup Analysis of a Randomized Placebo-Controlled Trial International Journal of Radiation OncologyBiologyPhysics ·Christopher A. Barker, C.A. Cella, D. Bartsch, Jonathan D. Schoenfeld, F. Stephen Hodi, Douglas B. Johnson, Jedd D. Wolchok	2017	1
15	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab Cancer Immunology Research ·Amanara Potykytã, Richard W. Joseph, Chengwei Peng, Fei Ye, Shilin Zhao, Igor Puzanov, Jeffrey A. Sosman, Douglas B. Johnson	2016	16
16	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti–PD-1 Therapy Cancer Immunology Research ·Allison R. Greenplate, Douglas B. Johnson, Mikaël Roussel, Michael R. Savona, Jeffrey A. Sosman, Igor Puzanov, P. Brent Ferrell, Jonathan M. Irish	2016	16
17	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies Cancer Immunology Research ·Douglas B. Johnson, Christine M. Lovly, Marisa Flavin, Katherine S. Panageas, Gregory D. Ayers, Zhiguo Zhao, Wade T. Iams, Alvaro Macieira Coelho, H. Bernard-Maître, Charles R. Terry, Elizabeth Berry, A. John Iafrate, Ryan J. Sullivan, Richard D. Carvajal, Jeffrey A. Sosman	2015	132
18	Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy Clinical Cancer Research ·Daniel N. Cohen, Sumit Malagoudanavar, Aaron C. Shaver, Liping Du, Harrison P. Nguyen, Qin He, Douglas B. Johnson, Christophe Chenon, Brent R. Moody, James L. Prescott, Pranil Chandra, Alan S. Boyd, Jeffrey P. Zwerner, Dita Gadis Kardena, Stephen K. Tyring, Peter L. Rady, James D. Chappell, Yu Shyr, Jeffrey R. Infante, Jeffrey A. Sosman	2015	23
19	A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance Molecular Cancer Therapeutics ·Junfeng Xia, Peilin Jia, Katherine E. Hutchinson, Kimberly B. Dahlman, Douglas B. Johnson, Jeffrey A. Sosman, William Pao, Zhongming Zhao	2014	65
20	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Cancer Discovery ·Hubing Shi, Willy Hugo, Xiangju Kong, Aayoung Hong, Richard C. Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B. Johnson, Kimberly B. Dahlman, Mark C. Kelley, Richard Kefford, Bartosz Chmielowski, John A. Glaspy, Jeffrey A. Sosman, Nicolas van Baren, Georgina V. Long, Antoni Ribas, Roger S. Lo Hit paper breakdown →	2013	715

About Douglas B. Johnson

Douglas B. Johnson is a scholar working on Oncology, Immunology, Molecular Biology, Cancer Research and Genetics, having authored 293 papers that have together received 14.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (190 papers), CAR-T cell therapy research (93 papers), Melanoma and MAPK Pathways (90 papers), Immunotherapy and Immune Responses (62 papers), Cutaneous Melanoma Detection and Management (43 papers), Colorectal Cancer Treatments and Studies (33 papers), Cancer Genomics and Diagnostics (22 papers) and Lung Cancer Treatments and Mutations (15 papers). The work is most often cited by research in Oncology (9.8k citations), Immunology (4.0k citations), Genetics (839 citations), Cancer Research (1.1k citations) and Pulmonary and Respiratory Medicine (2.4k citations). Douglas B. Johnson has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Jeffrey A. Sosman, Justin M. Balko, Satya Das, Javid J. Moslehi, Ryan J. Sullivan, Caroline A. Nebhan, Alexander M. Menzies, Igor Puzanov, Mark C. Kelley and Georgina V. Long. Their work appears in journals such as Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, The Oncologist, Annals of Oncology and Cancer Immunology Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact